The CYP3A4*18 allele, the most frequent coding variant in Asian populations, does not significantly affect the midazolam disposition in heterozygous individuals

Drug Metabolism and Disposition

Volumn 35, Issue 11, 2007, Pages 2095-2101

  Lee, Su Jun ^a   Sang, Seop Lee ^a   Jeong, Hye Eun ^a   Shon, Ji Hong ^a   Ryu, Ji Young ^a   Yu, Eun Sunwoo ^a   Liu, Kwang Hyeon ^a   Kang, Wonku ^a,b   Park, Young Ju ^a   Shin, Chi Mann ^a   Shin, Jae Gook ^a,c  

^a Inje University College of Medicine   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; MIDAZOLAM; 1-HYDROXYMETHYLMIDAZOLAM; 4 HYDROXYMIDAZOLAM; 4-HYDROXYMIDAZOLAM; ALPHA HYDROXYMIDAZOLAM; ANXIOLYTIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; DRUG DERIVATIVE; ISOENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; ASIA; BACULOVIRUS; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENE FREQUENCY; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; KOREA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; ASIAN; BLOOD; CATALYSIS; GENETICS; HETEROZYGOTE; KINETICS; METABOLISM; SPECTROPHOTOMETRY;

ADULT; ANTI-ANXIETY AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; HETEROZYGOTE; HUMANS; ISOENZYMES; KINETICS; KOREA; MIDAZOLAM; NADPH-FERRIHEMOPROTEIN REDUCTASE; POLYMORPHISM, SINGLE NUCLEOTIDE; SPECTROPHOTOMETRY;

EID: 35548982614     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016733     Document Type: Article

References (52)

1. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, and Rebbeck TR (2003) Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 42:299-305.
2. Cavaco I, Gil JP, Gil-Berglund E, and Ribeiro V (2003) CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med 41:1345-1350.
3. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, and Goldstein JA (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825-831.
4. Du J, Xing Q, Xu L, Xu M, Shu A, Shi Y, Yu L, Zhang A, Wang L, Wang H, et al. (2006) Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 7:831-841.
5. Eap CB, Buclin T, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, and Kerb R (2004) Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 60:231-236.
6. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, et al. (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-458.
7. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, and Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606.
8. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, et al. (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23:100.
9. Garcia-Martin E, Martinez C, Pizarro RM, Garcia-Gamito FJ, Gullsten H, Raunio H, and Agundez JA (2002) CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 71:196-204.
10. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90.
11. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
12. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, and Wallemacq P (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147-154.
13. He P, Court MH, Greenblatt DJ, and Von Moltke LL (2005) Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77:373-387.
14. He P, Court MH, Greenblatt DJ, and von Moltke LL (2006) Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. J Clin Pharmacol 46:1356-1369.
15. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, and van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254.
16. Ho SN, Hunt HD, Horton RM, Pullen JK, and Pease LR (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59.
17. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, and Huang JD (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29:268-273.
18. Hu YF, He J, Chen GL, Wang D, Liu ZQ, Zhang C, Duan LF, and Zhou HH (2005) CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 353:187-192.
19. Kashuba AD, Bertino JS, Jr., Rocci ML, Jr., Kulawy RW, Beck DJ, and Nafziger AN (1998) Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 64:269-277.
20. Khan KK, He YQ, Domanski TL, and Halpert JR (2002) Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495-506.
21. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408-414.
22. Komori M, Nishio K, Kitada M, Shiramatsu K, Muroya K, Soma M, Nagashima K, and Kamataki T (1990) Fetus-specific expression of a form of cytochrome P-450 in human livers. Biochemistry 29:4430-4433.
23. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
24. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002a) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
25. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, and Schuetz EG (2002b) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121-132.
26. Lee SJ, Bell DA, Coulter SJ, Ghanayem B, and Goldstein JA (2005a) Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther 313:302-309.
27. Lee SJ and Goldstein JA (2005) Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 6:357-371.
28. Lee SS, Jeong HE, Liu KH, Ryu JY, Moon T, Yoon CN, Oh SJ, Yun CH, and Shin JG (2005b) Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet Genomics 15:105-113.
29. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
30. Matsumura K, Saito T, Takahashi Y, Ozeki T, Kiyotani K, Fujieda M, Yamazaki H, Kunitoh H, and Kamataki T (2004) Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol Pharmacol 65:326-334.
31. Min DI and Ellingrod VL (2003) Association of the CYP3A4*1B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 25:305-309.
32. Murayama N, Nakamura T, Saeki M, Soyama A, Saito Y, Sai K, Ishida S, Nakajima O, Itoda M, Ohno Y, et al. (2002) CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation. Drug Metab Pharmacokinet 17:150-156.
33. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239:2379-2385.
34. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, and Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388.
35. Rivory LP, Qin H, Clarke SJ, Eris J, Duggin G, Ray E, Trent RJ, and Bishop JF (2000) Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. Eur J Clin Pharmacol 56:395-398.
36. Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, and Roger M (2005) CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 33:884-887.
37. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, and Gonzalez FJ (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56.
38. Shih PS and Huang JD (2002) Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 30:1491-1496.
39. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
40. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, and Daly AK (2003) Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-1235.
41. Thummel KE (2003) Does the CYP3A5*3 polymorphism affect in vivo drug elimination? Pharmacogenetics 13:585-587.
42. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
43. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, and Wilkinson GR (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 68:82-91.
44. Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AY (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366.
45. Westlind A, Lofberg L, Tindberg N, Andersson TB, and Ingelman-Sundberg M (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259:201-205.
46. Westlind-Johnsson A, Hermann R, Huennemeyer A, Hauns B, Lahu G, Nassr N, Zech K, Ingelman-Sundberg M, and von Richter O (2006) Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther 79:339-349.
47. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761.
48. Wilkinson GR (2004) Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions. Clin Pharmacol Ther 76:99-103.
49. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891.
50. Yamamoto T, Nagafuchi N, Ozeki T, Kubota T, Ishikawa H, Ogawa S, Yamada Y, Hirai H, and Iga T (2003) CYP3A4*18: it is not rare allele in Japanese population. Drug Metab Pharmacokinet 18:267-268.
51. Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, et al. (2004) Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 76:104-112.
52. Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q, and Wang W (2005) Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 37:178-181.